XOMA Corporation (XOMA)
| Market Cap | 297.95M |
| Revenue (ttm) | 5.81M |
| Net Income (ttm) | -45.09M |
| Shares Out | 11.64M |
| EPS (ttm) | -3.92 |
| PE Ratio | n/a |
| Forward PE | 30.49 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,714 |
| Open | 25.51 |
| Previous Close | 25.51 |
| Day's Range | 25.51 - 25.89 |
| 52-Week Range | 13.48 - 27.00 |
| Beta | 0.57 |
| Analysts | Strong Buy |
| Price Target | 57.00 (+122.66%) |
| Earnings Date | May 9, 2024 |
About XOMA
XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various... [Read more]
Financial Performance
In 2023, XOMA's revenue was $4.76 million, a decrease of -21.06% compared to the previous year's $6.03 million. Losses were -$46.30 million, 105.1% more than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for XOMA stock is "Strong Buy." The 12-month stock price forecast is $57.0, which is an increase of 122.66% from the latest price.
News
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
EMERYVILLE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that members of its Executive Team will participate in the H.C. Wa...
XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
Earned $9 million milestone upon U.S. Food and Drug Administration's approval of Day One's OJEMDA™ (tovorafenib); XOMA is entitled to receive a mid-single digit royalty on OJEMDA™ sales
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
XOMA is entitled to a mid-single digit royalty on global OJEMDA™ sales First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearra...
Actym Therapeutics Appoints Thomas Smart as CEO
BERKELEY, Calif. , April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer.
XOMA Corporation Announces Closing of Tender Offer
EMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) (“XOMA” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biotech compa...
XOMA Declares Quarterly Preferred Stock Dividends
EMERYVILLE, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to h...
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
EMERYVILLE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- As previously announced on February 16, 2024, XOMA Corporation (“XOMA” or the “Company”; Nasdaq: XOMA) entered into a merger agreement to acquire...
KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Kinnate Biopharm...
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
Raised up to $140 million of non-dilutive non-recourse capital through a royalty-backed loan related to VABYSMO® from funds managed by Blue Owl Capital
XOMA to Present at Upcoming Investor Conferences in March
EMERYVILLE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following M...
KINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Kinnate Biopharm...
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
EMERYVILLE, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today it has entered an agreement to acquire Kinnate Biopharma Inc. (NASDAQ: KNTE) for (i) a base cash p...
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition
XOMA provided an $8 million non-dilutive royalty capital solution to Talphera XOMA will receive a 15% royalty on all commercial sales and a significant portion of the 75% royalty generated by U.S. Dep...
FDA Acceptance of Zevra's Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx
FDA has acknowledged receipt of the resubmission and assigned a PDUFA target action date of June 21, 2024 FDA has acknowledged receipt of the resubmission and assigned a PDUFA target action date of Ju...
XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors
EMERYVILLE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today the Board of Directors has named Owen Hughes as Chief Executive O...
XOMA Announces Stock Repurchase Program of up to $50 Million
XOMA to repurchase up to $50M of its stock before January 2027. Management actively participating in capital structure to maximize shareholder value.
XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties
Low-cost financing capitalizes on XOMA's $14 million acquisition of VABYSMO® (faricimab) royalties in 2021
XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value
Received $6.6 million in cash receipts during the quarter related to our growing royalty base and certain development milestones
XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One's Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
FDA has granted Priority Review and assigned a PDUFA target action date of April 30, 2024 FDA has granted Priority Review and assigned a PDUFA target action date of April 30, 2024
XOMA to Present at H.C. Wainwright 25th Annual Global Investment Conference
EMERYVILLE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the Biotech Royalty Aggregator, announced today Owen Hughes, Executive Chairman, will present a company update a...
XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy
Completed two royalty acquisitions in the first half of 2023 adding one cash flow generating asset, one NDA-ready asset, and a Phase 2 asset
XOMA Added to the Russell 2000® and Russell 3000® Indexes
EMERYVILLE, Calif., June 23, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced it has been added to the Russell 2000® and Russell 3000® Indexes follow...
XOMA Acquires Royalty and Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) and Phase 2 Oncology Asset
New Drug Application for arimoclomol in NPC to be filed as early as the third quarter of 2023¹ New Drug Application for arimoclomol in NPC to be filed as early as the third quarter of 2023¹
LadRx Completes Non-Dilutive Financing Transaction for up to $11 Million with XOMA Corporation
LOS ANGELES--(BUSINESS WIRE)--LadRx Corporation (OTCQB: LADX) ("LadRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today an...
XOMA Reports First Quarter 2023 Financial Results and Provides Update on the Acceleration of its Differentiated Royalty Monetization Strategy
First quarter with incoming cashflows from two commercial assets Completed first royalty asset acquisition under new leadership EMERYVILLE, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (N...